New Mesothelioma Drug Trial Begins

mesothelioma drug trial

A new mesothelioma drug trial is now underway. The trial will test a brand new type of immunotherapy medication called CA-170. CA-170 is designed to block an immune system suppressor called VISTA. It is the only VISTA-blocking medication currently in clinical trial. “CA-170 has demonstrated favorable safety and tolerability as well as preliminary anti-tumor activity in patients across multiple tumor types,” the company said in a statement. Mesothelioma Drug Trial Focuses on VISTA Malignant mesothelioma is highly resistant to standard cancer treatments. Many top researchers believe that immunotherapy drugs offer the best promise for curing mesothelioma. That is because cancers like malignant mesothelioma survive in part by evading detection by the immune system. They do this in a variety ways … Continue reading New Mesothelioma Drug Trial Begins »

MIT Study Could Open Door for Inhalable Mesothelioma Treatment

inhalable mesothelioma treatment tested on lab mice

New lung cancer research might help pave the way for an inhalable mesothelioma treatment. MIT cancer researchers teamed up with chemical engineers to test a new method for delivering genetic instructions to lung cells. Mice that inhaled a formula designed to “tell” their lung cells to produce more of a certain protein did exactly that. The team says it’s proof that this could be a viable method for treating cancer in the lungs. Pleural mesothelioma is a lung-related cancer caused by inhaled asbestos. How Would an Inhalable Mesothelioma Treatment Work? The study was led by scientists at MIT’s Koch Center for Integrative Cancer Research. It is based on two things scientists already know about cancer treatment. One is that inhalation … Continue reading MIT Study Could Open Door for Inhalable Mesothelioma Treatment »

Survival After Mesothelioma Surgery Could Rise with Immunotherapy Spray

improving survival after mesothelioma surgery

A spray-on immune booster may one day improve survival after mesothelioma surgery. UCLA scientists tested the biodegradable spray gel in mice with advanced melanoma. They found that it stopped cancer recurrence after surgery in about half of the lab animals tested. “Around 90 percent of people with cancerous tumors end up dying because of tumor recurrence or metastasis,” says lead investigator Zhen Gu. “Being able to develop something that helps lower this risk for this to occur and has low toxicity is especially gratifying.” Gu is a professor of bioengineering and a member of the UCLA Jonsson Comprehensive Cancer Center where the spray was developed. Survival After Mesothelioma Surgery Survival after mesothelioma surgery or any other kind of cancer operation … Continue reading Survival After Mesothelioma Surgery Could Rise with Immunotherapy Spray »

Immunotherapy for Peritoneal Mesothelioma: New Drug Trial Begin

immunotherapy for peritoneal mesothelioma

Researchers in Maryland and Missouri have started human testing of a new type of immunotherapy for peritoneal mesothelioma. If the human trial of this new CAR T-cell therapy goes as well as the laboratory tests, this could be good news for many people with asbestos cancer. CAR stands for chimeric antigen receptor. CAR T-cell therapy works by “reprogramming” a patient’s immune system to fight cancer cells. Tests show this therapy can work well for blood-based cancers like leukemia. But the results have not been as good for solid tumors like peritoneal mesothelioma. MaxCyte is the American company than makes the new drug. They are hoping that their approach to immunotherapy for peritoneal mesothelioma will be better. Preparing CAR T-cell Therapy … Continue reading Immunotherapy for Peritoneal Mesothelioma: New Drug Trial Begin »

Genetics-Based Cancer Treatment Could Mean New Hope for Mesothelioma

genetic-based cancer treatment for targeted mesothelioma therapy

The FDA has approved a new genetics-based cancer treatment that could open the door for more targeted mesothelioma therapy. The drug is called larotrectinib. The drug company Bayer sells it under the brand name Vitrakvi. Larotrectinib is unique because it is not specific to any one type of cancer. Instead, larotrectinib is based on a patient’s genetic biomarkers. It is the first drug of its kind to gain approval by the FDA. What is a Genetics-Based Cancer Treatment? A genetics-based cancer treatment is a drug that targets certain genetic mutations. Doctors find these mutations by testing for biomarkers. One mutation could cause breast cancer, colon cancer, or even pleural mesothelioma. Some kinds of mutations are connected to only one type … Continue reading Genetics-Based Cancer Treatment Could Mean New Hope for Mesothelioma »

Study Suggests Sugar Supplement Could Slow Growth of Mesothelioma

nutritional supplement fights cancer

A sugar supplement might be able to slow the growth of mesothelioma and others types of cancer. The sugar supplement is called mannose. Mannose occurs naturally in some fruits, including cranberries. It is also sold as a nutritional supplement. Researchers with Cancer Research UK and Worldwide Cancer Research say mannose slowed the growth of tumors in mice. The test mice had leukemia, bone cancer, ovarian cancer, or bowel cancer. In a new report in the journal Nature, the researchers say mannose made mouse tumors smaller. It also helped chemotherapy work better and helped some mice live longer. How Does Mannose Slow Tumor Growth? All cells in the body need glucose to grow. This includes cancer cells. Cancers like mesothelioma need … Continue reading Study Suggests Sugar Supplement Could Slow Growth of Mesothelioma »

When Chemotherapy Fails: Apatinib May Offer Third-Line Option for Mesothelioma Patients

An investigational drug being developed in China may offer a third lifeline to mesothelioma patients whose cancer does not respond to other chemotherapy drugs. Apatinib, also called YN968D1, is a tyrosine kinase inhibitor that is thought to help prevent the formation of blood vessels that mesothelioma tumors need to grow and spread. Right now, there is no approved second-line treatment for pleural mesothelioma, let alone a third-line treatment. Chinese researchers at 363 Hospital in Cheng Du — along with mesothelioma patients around the world — are hoping that apatinib will change that. Mesothelioma Case Study The researchers are hanging their hopes on the case of a 58-year old woman who showed up at their hospital complaining that she had had … Continue reading When Chemotherapy Fails: Apatinib May Offer Third-Line Option for Mesothelioma Patients »

Ofev Fails to Boost Mesothelioma Survival in New Study

In the quest to develop new, more effective first-line treatments for malignant pleural mesothelioma, it now looks like Ofev (nintedanib) is out of the running. Phase III results of the LUME-Meso mesothelioma trial are in and they contain some disappointing news for mesothelioma patients and for the drug’s developer, Boehringer Ingelheim. The news is especially disappointing since the results of the Phase II portion of the trial, released last year, looked promising. At that time, researchers reported a survival gain of more than 5 months among the Ofev-treated mesothelioma patients and progression-free survival of four months. But further research did not support those results, as investigators announced to the world’s lung cancer experts at the IASLC 19th World Lung Cancer … Continue reading Ofev Fails to Boost Mesothelioma Survival in New Study »

Old Drug May Breath New Life Into Mesothelioma Radiotherapy

Researchers at the University of Ohio may have found a way to make radiation therapy more effective for people with mesothelioma and other types of solid tumors. They’re using a muscle relaxant approved in the 1800s to increase the level of oxygen in cancer cells and make them more susceptible to the damaging effects of radiation. The research could have wide-ranging implications, especially for patients fighting treatment-resistant malignancies like pleural mesothelioma. The Limitations of Radiation for Pleural Mesothelioma Mesothelioma is a fast-growing cancer associated with asbestos exposure that occurs on the membranes around internal organs. Although the irregular shape and tricky location of mesothelioma tumors can make them difficult to treat with radiotherapy, advanced targeting techniques are making it more … Continue reading Old Drug May Breath New Life Into Mesothelioma Radiotherapy »

Is it Time for a Curcumin-Based Mesothelioma Treatment?

Yet another scientific study appears to confirm the power of the spice-derived compound curcumin as a weapon against malignant pleural mesothelioma. The Chinese researchers who conducted the latest study say the substance has the potential to be the basis of a whole new way of treating this aggressive asbestos cancer. This team tested curcumin on a line of mouse mesothelioma cells, both in the lab and in live animals, and published their promising results in the prestigious International Journal of Oncology. Curcumin’s Impact on Mesothelioma Cells Curumin is a primary chemical in turmeric, responsible for the root’s spicy flavor and characteristic yellow hue. If turmeric does, in fact, help fight cancer, as so many health food stores and supplement makers … Continue reading Is it Time for a Curcumin-Based Mesothelioma Treatment? »

Get your free copy of
“Surviving Mesothelioma” Today!